Approaches to handling pharmacodynamic baseline responses

被引:66
作者
Dansirikul, Chantaratsamon [1 ]
Silber, Hanna E. [1 ]
Karlsson, Mats O. [1 ]
机构
[1] Uppsala Univ, Div Pharmacokinet & Drug Therapy, Dept Pharmaceut Biosci, SE-75124 Uppsala, Sweden
关键词
baseline responses; baseline model; pharmacokinetics; pharmacodynamics;
D O I
10.1007/s10928-008-9088-2
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
A few approaches for handling baseline responses are available for use in pharmacokinetic (PK)-pharmacodynamic (PD) analysis. They include: (method 1-B1) estimation of the typical value and interindividual variability (IIV) of baseline in the population, (B2) inclusion of the observed baseline response as a covariate acknowledging the residual variability, (B3) a more general version of B2 as it also takes the IIV of the baseline in the population into account, and (B4) normalization of all observations by the baseline value. The aim of this study was to investigate the relative performance of B1-B4. PD responses over a single dosing interval were simulated from an indirect response model in which a drug acts through stimulation or inhibition of the response according to an Emax model. The performance of B1-B4 was investigated under 22 designs, each containing 100 datasets. NONMEM VI beta was used to estimate model parameters with the FO and the FOCE method. The mean error (ME, %) and root mean squared error (RMSE, %) of the population parameter estimates were computed and used as an indicator of bias and imprecision. Absolute ME (vertical bar ME vertical bar) and RMSE from all methods were ranked within the same design, the lower the rank value the better method performance. Average rank of each method from all designs was reported. The results showed that with B1 and FOCE, the average of |ME| and RMSE across all typical individual parameters and all conditions was 5.9 and 31.8%. The average rank of |ME| for B1, B2, B3, and B4 was 3.7, 3.8, 3.3, and 5.2 for the FOCE method, and 4.6, 4.3, 4.7, and 6.4 for the FO method. The smallest imprecision was noted with the use of B1 (rank of 3.1 for FO, and 2.9 for FOCE) and increased, in order, with B3 (3.9-FO and 3.6-FOCE), B2 (4.8-FO; 4.7-FOCE), and B4 (6.4-FO; 6.5-FOCE). We conclude that when considering both bias and imprecision B1 was slightly better than B3 which in turn was better than B2. Differences between these methods were small. B4 was clearly inferior. The FOCE method led to a smaller bias, but no marked reduction in imprecision of parameter estimates compared to the FO method.
引用
收藏
页码:269 / 283
页数:15
相关论文
共 17 条
[1]   Pharmacodynamics of controlled release verapamil in patients with hypertension: An analysis using spline functions [J].
Aarons, L ;
Baxter, C ;
Gupta, S .
BIOPHARMACEUTICS & DRUG DISPOSITION, 2004, 25 (05) :219-225
[2]  
BEAL SL, 1994, NONMEM USERS GUIDE
[3]   Population pharmacodynamic analysis of octreotide in acromegalic patients [J].
Comets, E ;
Mentré, F ;
Grass, P ;
Kawai, R ;
Marbach, P ;
Vonderscher, J .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2003, 73 (01) :95-106
[4]   COMPARISON OF 4 BASIC MODELS OF INDIRECT PHARMACODYNAMIC RESPONSES [J].
DAYNEKA, NL ;
GARG, V ;
JUSKO, WJ .
JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1993, 21 (04) :457-478
[5]   Pharmacokinetic and pharmacodynamic analysis of TS-943, a selective non-peptide platelet glycoprotein-IIb/IIIa (GPIIb/IIIa) receptor antagonist, using a nonlinear mixed effect model in dogs [J].
Furuya, A ;
Nozawa, M ;
Gotoh, J ;
Jingu, S ;
Akimoto, M ;
Higuchi, S ;
Suwa, T ;
Ogata, H .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 2002, 54 (07) :921-927
[6]  
HUGH BM, 2004, PAGE ANN M POP APPR
[7]   The population pharmacokinetics of recombinant- and urinary-human follicle stimulating hormone in women [J].
Karlsson, MO ;
Wade, JR ;
Loumaye, E ;
Munafo, A .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1998, 45 (01) :13-20
[8]   PsN-Toolkit - A collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM [J].
Lindbom, L ;
Pihlgren, P ;
Jonsson, N .
COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE, 2005, 79 (03) :241-257
[9]  
LISENFELD K, 2005, PAGE ANN M POP APPR
[10]   Design of biological equivalence programs for therapeutic biotechnology products in clinical development: A perspective [J].
Mordenti, J ;
Cavagnaro, JA ;
Green, JD .
PHARMACEUTICAL RESEARCH, 1996, 13 (10) :1427-1437